Adverse event development in clinical oncology trials – Authors' reply

Research output: Contribution to journalLetter

Original languageEnglish (US)
Pages (from-to)e264-e265
JournalThe Lancet Oncology
Volume17
Issue number7
DOIs
StatePublished - Jul 1 2016

Fingerprint

Medical Oncology
Clinical Trials

ASJC Scopus subject areas

  • Oncology

Cite this

Adverse event development in clinical oncology trials – Authors' reply. / Thanarajasingam, Gita; Sloan, Jeff A; Grothey, Axel F.

In: The Lancet Oncology, Vol. 17, No. 7, 01.07.2016, p. e264-e265.

Research output: Contribution to journalLetter

@article{e3bc4bf9a8524fcaafb7bcd8d140032b,
title = "Adverse event development in clinical oncology trials – Authors' reply",
author = "Gita Thanarajasingam and Sloan, {Jeff A} and Grothey, {Axel F}",
year = "2016",
month = "7",
day = "1",
doi = "10.1016/S1470-2045(16)30245-5",
language = "English (US)",
volume = "17",
pages = "e264--e265",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "7",

}

TY - JOUR

T1 - Adverse event development in clinical oncology trials – Authors' reply

AU - Thanarajasingam, Gita

AU - Sloan, Jeff A

AU - Grothey, Axel F

PY - 2016/7/1

Y1 - 2016/7/1

UR - http://www.scopus.com/inward/record.url?scp=84991073154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991073154&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(16)30245-5

DO - 10.1016/S1470-2045(16)30245-5

M3 - Letter

C2 - 27396640

AN - SCOPUS:84991073154

VL - 17

SP - e264-e265

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 7

ER -